Overview

Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy

Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
0
Participant gender:
All
Summary
To assess the efficacy of treatment with sitagliptin or dapagliflozin or lobeglitazone in type 2 diabetes mellitus patients, who had inadequate glycemic control even though use of two drug combination therapy with glimepiride and metformin.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Seoul National University Bundang Hospital
Treatments:
Dapagliflozin
Metformin
Sitagliptin Phosphate
Criteria
Inclusion Criteria:

- 20 ≤ Age < 80 years

- HbA1c ≥ 7 %

- combination therapy with glimepiride and metformin over 2 months.

- dosage of glimepiride : 1-8mg/day

- dosage of metformin : 500-2550mg/day

Exclusion Criteria:

- Type 1 diabetes, gestational diabetes, or secondary forms of diabetes

- Contraindication to sitagliptin or dapagliflozin or lobeglitazone

- Pregnant or breast feeding women

- Medication which affect glycemic control (ex. steroid)

- Disease which affect efficacy and safety of drugs

- Any major illness (Liver disease, Renal failure, Heart disease, Cancer, etc)

- Not appropriate for oral antidiabetic agent